drugset / Trial / NCT01085123
Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers
Non-randomizedSingle-groupOpen-labelBasic science
Summary
The purpose of this study is to determine the central 5-HT1B receptor occupancy of ZOMIG® Rapimelt (zolmitriptan) in healthy male volunteers.
Timeline
- Start
- 2010-05
- Primary completion
- 2010-10
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zolmitriptan | Small molecule | 2.5 mg | Oral |
| Subject | Zolmitriptan | Small molecule | 5 mg | Oral |
| Subject | Zolmitriptan | Small molecule | 10 mg | Oral |
| Subject | [11C]AZ10419369 | Unknown | — | Intravenous |